The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Selective Serotonin-Reuptake Inhibitor–Induced Movement Disorders
Abstract
OBJECTIVE: To compile and evaluate all available data suggesting an association between selective serotonin-reuptake inhibitor (SSRI) administration and the occurrence of movement disorders, and to characterize these reactions in terms of onset, duration, treatment and outcome, and potential predisposing factors. METHODOLOGY: Reports of movement disorders were identified by conducting a comprehensive literature search that included tertiary adverse drug reaction resources, MEDLINE, EmBASE, Biological Abstracts, Current Contents, Reactions, ClinAlert, and International Pharmaceutical Abstracts. In addition, reports were solicited from the Canadian proprietary manufacturers of SSRIs, and from the Therapeutic Products Program of Health Canada. Each case was then classified according to the description of the movement disorder, based on predefined diagnostic criteria. RESULTS: A total of 127 published reports of SSRI-induced movement disorders were identified involving akathisia (n = 30), dystonia (19), dyskinesia (12), tardive dyskinesia (6), parkinsonism (25), and 15 cases of mixed disorders. Ten isolated cases of bruxism were identified. Ten additional reports could not be classified. Manufacturers of SSRIs provided 49 reports of akathisia, 44 of dystonia, 208 of dyskinesia, 76 of tardive dyskinesia, 516 of parkinsonism, and 60 of bruxism. Treatment strategies included discontinuation of the SSRI; dosage reduction; or the addition of a benzodiazepine, β-blocker, or anticholinergic agent. CONCLUSIONS: SSRI use appears to be associated with the development of movement disorders, as either a direct result of the drug or exacerbation of an underlying condition. Predisposing factors may include the use of neuroleptics, existing neurologic diagnoses, or preexisting movement disorders. Clinicians should be cognizant of the potential for these reactions, as prompt recognition and management is essential in preventing potentially significant patient morbidity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Pharmacotherapy: A Pathophysiologic Approach
(1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-5-447_3 · Cited by 2,407
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Hastings, R. C., & Long, G. W. (1991) · JAMA · doi:10.1001/jama.1991.03460200114048 · Cited by 1,060
Drugs and the treatment of psychiatric disorders
Baldessarini, R. J. (1996) · Medical Entomology and Zoology · Cited by 683
Movement Disorders Associated With the Serotonin Selective Reuptake Inhibitors
Leo, R. J. (1996) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v57n1002 · Cited by 364
Binding of antidepressants to human brain receptors: focus on newer generation compounds
Cusack, B., Nelson, A., & Richelson, E. (1994) · Psychopharmacology · doi:10.1007/bf02244985 · Cited by 349
Fluoxetine-induced akathisia: clinical and theoretical implications.
Lipinski, J. F., Mallya, G. K., Zimmerman, P., & Pope, H. G. (1989) · PubMed · Cited by 279
SSRI-associated nocturnal bruxism in four patients.
Ellison, J. M., & Stanziani, P. J. (1993) · PubMed · Cited by 167
Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant
Meltzer, H. Y., Young, M., Metz, J., Fang, V. S., Schyve, P. M., & Arora, R. C. (1979) · Journal of Neural Transmission · doi:10.1007/bf01250091 · Cited by 167
Fluoxetine and extrapyramidal side effects
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.1.122 · Cited by 158
Cited by
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612
Fava, M., & Kendler, K. S. (2000) · Neuron · doi:10.1016/s0896-6273(00)00112-4 · Cited by 603
N eurobiological M echanisms I nvolved in S leep B ruxism
Lavigne, G. J., Kato, T., Kolta, A., & Sessle, B. J. (2003) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130301400104 · Cited by 497
Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression
Mace, S., & Taylor, D. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.5.917 · Cited by 315
Sleep Bruxism: A Comprehensive Overview for the Dental Clinician Interested in Sleep Medicine
Carra, M. C., Huynh, N., & Lavigne, G. (2012) · Dental Clinics of North America · doi:10.1016/j.cden.2012.01.003 · Cited by 306
The non-motor syndrome of primary dystonia: clinical and pathophysiological implications
Stamelou, M., Edwards, M. J., Hallett, M., & Bhatia, K. P. (2012) · Brain · doi:10.1093/brain/awr224 · Cited by 299
Devos, D., Dujardin, K., Poirot, I., Moreau, C., Cottencin, O., Thomas, P., Destée, A., Bordet, R., & Defebvre, L. (2008) · Movement Disorders · doi:10.1002/mds.21966 · Cited by 274
Madhusoodanan, S., Alexeenko, L., Sanders, R., & Brenner, R. (2010) · Annals of Clinical Psychiatry · doi:10.1177/104012371002200303 · Cited by 121
Abad, V. C., & Guilleminault, C. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.4/vabad · Cited by 102
Persistent Sexual Side Effects after SSRI Discontinuation
Csoka, A. B., & Shipko, S. (2006) · Psychotherapy and Psychosomatics · doi:10.1159/000091777 · Cited by 92
Garland, E. J., & Baerg, E. A. (2001) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454601750284090 · Cited by 80
Dextromethorphan abuse: Clinical effects and management
Romanelli, F., & Smith, K. M. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.08091 · Cited by 77
FRIEDLANDER, A. H., FRIEDLANDER, I. K., & MARDER, S. R. (2002) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2002.0362 · Cited by 41
Benninghoff, J., van der Ven, A., Schloesser, R. J., Moessner, R., Möller, H. J., & Rujescu, D. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.640941 · Cited by 29
Metadata
- Authors
- Gerber, P. E., & Lynd, L. D.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 1998-06
- Volume
- 32
- Issue
- 6
- Pages
- 692-698
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2165743028
- Cited by
- 267
- References
- 33
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.